Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 Patients Treated with Concomitant CRRT
Open Access
- 1 March 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 7 (3), 452-457
- https://doi.org/10.2215/cjn.10741011
Abstract
Background and objectives Current recommendations for piperacillin-tazobactam dosing in patients receiving continuous renal replacement therapy originate from studies with relatively few patients and lower continuous renal replacement therapy doses than commonly used today. This study measured the pharmacokinetic and pharmacodynamic characteristics of piperacillin-tazobactam in patients treated with continuous renal replacement therapy using contemporary equipment and prescriptions. Design, setting, participants, & measurements A multicenter prospective observational study in the intensive care units of two academic medical centers was performed, enrolling patients with AKI or ESRD receiving piperacillin-tazobactam while being treated with continuous renal replacement therapy. Pregnant women, children, and patients with end stage liver disease were excluded from enrollment. Plasma and continuous renal replacement therapy effluent samples were analyzed for piperacillin and tazobactam levels using HPLC. Pharmacokinetic and pharmacodynamic parameters were calculated using standard equations. Multivariate analyses were used to examine the association of patient and continuous renal replacement therapy characteristics with piperacillin pharmacokinetic parameters. Results Forty-two of fifty-five subjects enrolled had complete sampling. Volume of distribution (median=0.38 L/kg, intraquartile range=0.20 L/kg) and elimination rate constants (median=0.104 h−1, intraquartile range=0.052 h−1) were highly variable, and clinical parameters could explain only a small fraction of the large variability in pharmacokinetic parameters. Probability of target attainment for piperacillin was 83% for total drug but only 77% when the unbound fraction was considered. Conclusions There is significant patient to patient variability in pharmacokinetic/pharmacodynamic parameters in patients receiving continuous renal replacement therapy. Many patients did not achieve pharmacodynamic targets, suggesting that therapeutic drug monitoring might optimize therapy.Keywords
This publication has 29 references indexed in Scilit:
- Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous HemodialysisAntimicrobial Agents and Chemotherapy, 2011
- Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyCritical Care, 2011
- Vancomycin‐Resistant Enterococcal Urinary Tract InfectionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- Therapeutic drug monitoring of β-lactams in critically ill patients: proof of conceptInternational Journal of Antimicrobial Agents, 2010
- Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shockCritical Care, 2010
- Prospective monitoring of cefepime in intensive care unit adult patientsCritical Care, 2010
- Intensity of Renal Support in Critically Ill Patients with Acute Kidney InjuryNew England Journal of Medicine, 2008
- Standard versus High-Dose CVVHDF for ICU-Related Acute Renal FailureJournal of the American Society of Nephrology, 2008
- Influence of Renal Function on the Pharmacokinetics of Piperacillin/Tazobactam in Intensive Care Unit Patients During Continuous Venovenous HemofiltrationThe Journal of Clinical Pharmacology, 2005
- Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous HemodialysisAntimicrobial Agents and Chemotherapy, 2002